28.98 0.076 (0.26%) | 05-20 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 34.07 | 1-year : | 39.8 |
Resists | First : | 29.17 | Second : | 34.07 |
Pivot price | 28.57 | |||
Supports | First : | 28.02 | Second : | 27.31 |
MAs | MA(5) : | 28.93 | MA(20) : | 28.34 |
MA(100) : | 28.84 | MA(250) : | 29.34 | |
MACD | MACD : | 0.1 | Signal : | 0 |
%K %D | K(14,3) : | 84.8 | D(3) : | 89.4 |
RSI | RSI(14): 60.4 | |||
52-week | High : | 31.39 | Low : | 27.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MEDX ] has closed below upper band by 20.8%. Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 29.05 - 29.21 | 29.21 - 29.36 |
Low: | 28.54 - 28.76 | 28.76 - 28.96 |
Close: | 28.67 - 28.98 | 28.98 - 29.27 |
The fund is an actively-managed exchange-traded fund (“ETF”) that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified.
Fri, 17 May 2024
Trend Tracker for (MEDX) - Stock Traders Daily
Wed, 01 May 2024
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook - Zacks Investment Research
Wed, 07 Feb 2024
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat - Zacks Investment Research
Fri, 03 Nov 2023
Eli Lilly Beats on Q3 Earnings: ETFs to Buy - Yahoo Finance
Thu, 22 Jun 2023
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout - Yahoo Finance
Thu, 22 Jun 2023
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout - Yahoo Lifestyle UK
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Financial Services
|
|
Industry:
Asset Management
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 0 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |